Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Number of employees : 30 250 people.
Sales per Business
20192020Delta
Innovative Medicines26 145.00100%42 518.00100% +62.62%
USD in Million
Sales per region
20192020Delta
United States15 342.0058.7%26 577.0062.5% +73.23%
Europe6 266.0024%9 853.0023.2% +57.25%
Rest of the World4 013.0015.3%5 457.0012.8% +35.98%
Other524.002%631.001.5% +20.42%
USD in Million
Managers
Name Title Age Since
Giovanni Caforio Chairman & Chief Executive Officer 55 2017
David Elkins Chief Financial Officer & Executive Vice President 51 -
Paul von Autenried Chief Information Officer & Executive VP 58 2019
Rupert Vessey Executive VP-Research & Early Development 55 2019
Joseph Eid Senior VP & Head-Global Medical Affairs 52 2017
Adam Dubow Senior VP, Chief Compliance & Ethics Officer 53 2018
Gerald L. Storch Independent Director 63 2012
Peter Arduini Independent Director 55 2016
Theodore Rapp Samuels Independent Director 65 2017
Karen H. Vousden, Dr. Independent Director 62 2018
Members of the board
Name Title Age Since
Giovanni Caforio Chairman & Chief Executive Officer 55 2017
Gerald L. Storch Independent Director 63 2012
Peter Arduini Independent Director 55 2016
Theodore Rapp Samuels Independent Director 65 2017
Karen H. Vousden, Dr. Independent Director 62 2018
Julia A. Haller, Dr. Director 65 2019
Phyllis R. Yale Director 62 2019
Paula A. Price Independent Director 58 2020
Derica W. Rice Independent Director 55 2020
Manuel Hidalgo Medina, Dr. Independent Director 52 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,923,000,000 2,220,606,635 76.0% 701,000,000 24.0% 76.0%
Shareholders
NameEquities%
Capital Research & Management Co. 203,897,400 9.18%
The Vanguard Group, Inc. 187,953,718 8.46%
SSgA Funds Management, Inc. 92,145,348 4.15%
JPMorgan Investment Management, Inc. 55,258,489 2.49%
Fidelity Management & Research Co. LLC 51,740,311 2.33%
BlackRock Fund Advisors 50,739,877 2.28%
Wellington Management Co. LLP 43,963,060 1.98%
Geode Capital Management LLC 35,957,818 1.62%
Dodge & Cox 28,473,658 1.28%
Northern Trust Investments, Inc.(Investment Management) 27,062,845 1.22%
Holdings
NameEquities%Valuation
ACCELERON PHARMA INC. (XLRN) 7,008,510 11.5% 938,299,319 USD
LYELL IMMUNOPHARMA, INC. (LYEL) 10,936,132 4.57% 172,681,524 USD
JW (CAYMAN) THERAPEUTICS CO. LTD (2126) 74,896,670 18.6% 158,897,030 USD
UNIQURE N.V. (QURE) 2,388,108 5.18% 69,255,132 USD
NURIX THERAPEUTICS, INC. (NRIX) 1,622,222 3.65% 52,219,326 USD
IDEAYA BIOSCIENCES, INC. (IDYA) 1,633,254 4.25% 38,381,469 USD
SUTRO BIOPHARMA, INC. (STRO) 1,726,197 3.74% 37,492,999 USD
CYTEIR THERAPEUTICS, INC. (CYT) 1,747,787 4.94% 33,347,776 USD
JOUNCE THERAPEUTICS, INC. (JNCE) 3,456,463 6.75% 21,499,200 USD
GALECTO, INC. (GLTO) 1,163,960 4.61% 5,179,622 USD
Markets and indexes
- International Market
- S&P 100 / S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx USA 50
Company contact information
Bristol-Myers Squibb Company
14th Floor 430 E Street 29th
NY 10016 New York City, New York

Phone : +1 212 546 4000
Fax :
web site : https://www.bms.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Bristol-Myers Squibb Company
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.98%128 216
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.12.52%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579
MERCK & CO., INC.-4.24%198 283
ABBVIE INC.1.64%192 463
ASTRAZENECA PLC20.34%186 771
NOVARTIS AG-8.60%185 154
SANOFI6.90%122 352
AMGEN INC.-10.06%117 421
GLAXOSMITHKLINE PLC4.46%95 969
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-27.49%57 298
BAYER AG-0.78%54 386
JIANGSU HENGRUI MEDICINE CO., LTD.-46.12%50 527
DAIICHI SANKYO COMPANY, LIMITED-16.76%49 253
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.93%44 698
ASTELLAS PHARMA INC.25.60%31 970
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY54.45%25 521